
Myeloproliferative Neoplasms (MPN)
Latest Content
Latest Videos

Shorts
More News

TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.

The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.

This new study from the VHA also shows neither cytoreductive therapy nor phlebotomy clearly lowers thrombosis risk.

Ropeginterferon alfa-2b-njft is expected to be available immediately.

Selinexor, an oral XPO1 inhibitor, delivers modest spleen volume reduction in ruxolitinib-refractory MF with minimal myelosuppression in ESSENTIAL trial news.

FDA approves rusfertide, a first-in-class hepcidin-mimetic for polycythemia vera, cutting phlebotomies and improving hematocrit control and QOL.

The findings reinforce monitoring and managing thrombotic risk across the PV population rather than focusing on traditionally defined high-risk patients.

Lab abnormalities can emerge between visits, and pharmacists may be able to catch uncontrolled hematocrit, adherence issues, or access barriers early.

This meta-analysis encompassed 18 studies published through December 31, 2025.

The authors suggest their data could reflect phlebotomy’s role as a reactive rather than sustained control measure.

Each visit incorporated instruments that included symptom burden, fatigue, anxiety and depression, nutritional risk, and patient activation.

Patients with a history of nonmelanoma skin cancer had a 548% greater likelihood to develop another skin cancer vs those with no cancer history.

INCA033989 demonstrated spleen reductions, anemia responses, and molecular improvements in patients with mutant calreticulin–positive myelofibrosis.

New research reveals ruxolitinib’s hidden cholesterol risk in patients who have MPN and pelabresib’s durable benefit when added to ruxolitinib in myelofibrosis.

Two abstracts from the 2026 ASCO annual meeting shed light on who is living with polycythemia vera in the US and what that experience is costing them.

These phase 3 studies are evaluating outcomes among patients living with polycythemia vera, myelofibrosis, and essential thrombocythemia.

Phlebotomy is used in polycythemia vera to reduce hematocrit levels below 45%, and is the most common treatment for the myeloproliferative neoplasm.

New research highlights INCA033989's potential in treating mutCALR-driven essential thrombocythemia and myelofibrosis, achieving significant molecular responses.

A new analysis suggests links between ZRSR2 loss and JAK2 V617R disease progression are indirect and complex.










